The Therapeutic Goods Administration (TGA) has approved the use of Global Sarcoma Therapy called YONDELISÒ, marketed by Specialised Therapeutics, for Australian patients afflicted with “unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen”. The approval comes after the drug therapy’s approval in 2015 for the United States and for Europe in 2007. Jayesh Desai, who is the Deputy-Chair of the Australia New Zealand Sarcoma Association (ANZSA) as well as an Associate Professor and Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia, stated, “Sarcoma is a relatively rare cancer and treatment options are limited for those with advanced disease. We welcome news that this therapy is formally approved for use in Australia and look forward to seeing advanced sarcoma patients being provided additional benefit.”
Read more here.